{
  "abstract": "BACKGROUND: Although lecanemab has demonstrated clinical efficacy in early Alzheimer's disease (AD), its cost‐effectiveness in China remains uncertain. This study evaluated the long‐term cost‐effectiveness of lecanemab in Chinese patients from a societal perspective and estimated its value‐based price (VBP).\n\nMETHODS: A Markov state transition model based on Chinese real‐world data was developed to compare the long‐term health progression and economic outcomes of lecanemab combined with standard of care (SoC) versus SoC alone.\n\nRESULTS: Compared to SoC alone, the lecanemab combination therapy gained an additional 1.2432 Quality‐adjusted life years (QALYs) at an incremental cost of 463,228 Chinese yuan (CNY), resulting in an incremental cost‐effectiveness ratio (ICER) of 372,609 CNY/QALY (≈ 52,783 USD/QALY). To achieve cost‐effectiveness within the willingness‐to‐pay threshold, the price of a single vial of lecanemab must be reduced by at least 18.0%.\n\nDISCUSSION: Lecanemab can provide health benefits to Chinese patients with early AD, but it is not cost‐effective under the current pricing system.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurology Institute of Neuroscience The Second Affiliated Hospital, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China Guangzhou Medical University Guangzhou China",
    "School of Public Health Guangzhou Medical University Guangzhou China",
    "The Second Affiliated Hospital Guangzhou Medical University Guangzhou China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Xingguang Zhao"
    },
    {
      "affs": [
        2
      ],
      "name": "Mingsong Xu"
    },
    {
      "affs": [
        0
      ],
      "name": "Hualin Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhixiang Lei"
    },
    {
      "affs": [
        0
      ],
      "name": "Qun Yu"
    },
    {
      "affs": [
        0
      ],
      "name": "Jun Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Wang Liao",
      "orcid": "0000-0001-7615-3626"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4hy78w74r5js3.bib",
  "cited_by": 0,
  "doi": "10.1002/alz.71941",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13714087/",
  "id": "4hy78w74r5js3",
  "issns": [
    "1552-5260",
    "1552-5279"
  ],
  "landing_url": "https://doi.org/10.1002/alz.71941",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2002|Health Systems, Economic Evaluations, Quality of Life"
    ]
  ],
  "openalex": "W7224135727",
  "pdf_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.71941",
  "pmcid": "PMC13714087",
  "pmid": "42947268",
  "published": "2026-10-27",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/4hy78w74r5js3.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T12:21:39Z",
      "native_id": "PMC13714087",
      "source": "pmc",
      "url": "https://doi.org/10.1002/alz.71941"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Cost‐effectiveness of lecanemab for early Alzheimer's disease in China",
  "title_text": "Cost‐effectiveness of lecanemab for early Alzheimer's disease in China",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:21:39Z",
  "url": "https://research.draconitic.com/paper/4hy78w74r5js3",
  "venue": "Alzheimer's & Dementia",
  "versions": []
}